ATE538791T1 - Medikament zur behandlung von glaukomen mit einer cyclodextrin-clathrat-verbindung aus cilostazol als wirkstoff - Google Patents

Medikament zur behandlung von glaukomen mit einer cyclodextrin-clathrat-verbindung aus cilostazol als wirkstoff

Info

Publication number
ATE538791T1
ATE538791T1 AT08792320T AT08792320T ATE538791T1 AT E538791 T1 ATE538791 T1 AT E538791T1 AT 08792320 T AT08792320 T AT 08792320T AT 08792320 T AT08792320 T AT 08792320T AT E538791 T1 ATE538791 T1 AT E538791T1
Authority
AT
Austria
Prior art keywords
cilostazole
glaucoma
cyclodextrin
medicine
treatment
Prior art date
Application number
AT08792320T
Other languages
English (en)
Inventor
Norio Okamoto
Yoshimasa Ito
Yoshimi Kawakami
Takuji Kurimoto
Noriaki Nagai
Tatsuya Yamashita
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE538791T1 publication Critical patent/ATE538791T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT08792320T 2007-08-02 2008-08-01 Medikament zur behandlung von glaukomen mit einer cyclodextrin-clathrat-verbindung aus cilostazol als wirkstoff ATE538791T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007202038 2007-08-02
JP2008050466 2008-02-29
PCT/JP2008/064263 WO2009017259A1 (en) 2007-08-02 2008-08-01 A medicament for treating glaucoma comprising as an active ingredient cyclodextrin-clathrate compound of cilostazol

Publications (1)

Publication Number Publication Date
ATE538791T1 true ATE538791T1 (de) 2012-01-15

Family

ID=39730869

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08792320T ATE538791T1 (de) 2007-08-02 2008-08-01 Medikament zur behandlung von glaukomen mit einer cyclodextrin-clathrat-verbindung aus cilostazol als wirkstoff

Country Status (11)

Country Link
US (1) US8686001B2 (de)
EP (1) EP2170332B1 (de)
JP (1) JP5236384B2 (de)
KR (1) KR20100051831A (de)
CN (1) CN101772345B (de)
AR (1) AR067746A1 (de)
AT (1) ATE538791T1 (de)
CA (1) CA2693364A1 (de)
ES (1) ES2376066T3 (de)
TW (1) TWI428128B (de)
WO (1) WO2009017259A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013001609A2 (pt) * 2010-07-22 2017-04-04 Merz Pharma Gmbh & Co Kgaa composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, uso de um composto de ciclodextrina
JP5822840B2 (ja) 2010-09-30 2015-11-24 ダイトーケミックス株式会社 眼疾患処置薬
TWI697337B (zh) 2013-08-07 2020-07-01 學校法人近畿大學 奈米粒子或奈米粒子組成物之製造方法,及支架或球囊導管之製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition

Also Published As

Publication number Publication date
JP5236384B2 (ja) 2013-07-17
ES2376066T3 (es) 2012-03-08
US8686001B2 (en) 2014-04-01
AR067746A1 (es) 2009-10-21
CA2693364A1 (en) 2009-02-05
US20110212993A1 (en) 2011-09-01
HK1140421A1 (en) 2010-10-15
JP2009227650A (ja) 2009-10-08
WO2009017259A1 (en) 2009-02-05
TW200908975A (en) 2009-03-01
KR20100051831A (ko) 2010-05-18
CN101772345A (zh) 2010-07-07
EP2170332B1 (de) 2011-12-28
EP2170332A1 (de) 2010-04-07
TWI428128B (zh) 2014-03-01
CN101772345B (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
EP2135858A4 (de) Zusammensetzung zur behandlung von infektionserkrankungen
EP2111223A4 (de) Aminderivatverbindungen zur behandlung von augenerkrankungen und -leiden
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
EP2415763A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von glaukom
EP2182983A4 (de) Behandlung von amyloidogenen erkrankungen
EP2579936A4 (de) Magensonde zur behandlung von adipositas
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
EP4091585C0 (de) Vorrichtung zur behandlung von refluxösophagitis
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK1876889T3 (da) Fungicide vandige sammensætninger til behandling af frø
EP2175873A4 (de) Behandlung von angstzuständen
EA201200098A1 (ru) Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия
ATE482939T1 (de) Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
DK2236149T3 (da) Medicinsk sammensætning til behandling af respiratoriske infektions-sygdomme
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
EP2249765A4 (de) Dapson zur behandlung von rosascea
ATE537178T1 (de) Neue klasse von spiro-piperidinen zur behandlung neurodegenerativer krankheiten
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
ATE472324T1 (de) Isosorbid-mononitrat-derivate zur behandlung von okularer hypertonie
ATE532787T1 (de) Polycyclische mittel zur behandlung von infektionen mit dem respiratory syncytial virus
ATE538791T1 (de) Medikament zur behandlung von glaukomen mit einer cyclodextrin-clathrat-verbindung aus cilostazol als wirkstoff
EP2195036A4 (de) Zusammensetzungen zur behandlung von tumoren durch direkte verabreichung eines radioisotops
EP2641604A4 (de) Zusammensetzung mit styraxlignolid oder aglycon daraus als wirkstoff zur vorbeugung oder behandlung von asthma